Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation

Abstract

Anti-HER2 monoclonal antibody (Sc7301)-paclitaxel (TAX) immunoconjugate was prepared and its specific binding to tumor cells was investigated in this study. Sc7301 was conjugated to TAX by the active ester method and then the TAX-Sc7301 immunoconjugate was obtained. After purification and labeling by Cyano-fluorescein isothiocyanate (FITC), the specific binding of TAX-Sc7301 to HER2-positive tumor cells (SKOV3) and HER2-negative tumor cells (HepG2) was evaluated respectively. TAX-Sc7301 (20 nmol/L) showed distinct specific binding to SKOV3 cells rather than HepG2 cells. And the uptake of the immunoconjugate by SKOV3 cells was increased with the TAX-Sc7301 concentration (3–48 nmol/L) and the incubation time (P<0.05). It was concluded that the TAX-Sc7301 immunoconjugate is potentially applicable as a targeted agent against HER2-positive tumor cells.

Keywords

paclitaxel / anti-HER2 monoclonal antibody / immunoconjugate / specific binding

References

[1] JaraczS., ChenJ., KuznetsovaL.V., et al.. Recent advances in tumor-targeting anticancer drug conjugates. Bioorg Med Chem, 2005, 13(17): 5043-5054

[2] ZhaoJ., CaoS.L., ZhengX.L., et al.. Folate receptor-mediated antitumor drugs. Yaoxue Xuebao (Chinese), 2009, 44(9): 109-114

[3] MilenicD.E., BrechbielM.W.. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther, 2004, 3(4): 361-370

[4] CamilleriB.S., Hardy-BessardA.C., LeT.A., et al.. HER2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the gineco group. Ann Oncol, 2004, 15(1): 104-122

[5] CaoY., MarksJ.D., MarksJ.W., et al.. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res, 2009, 69(23): 8987-8995

[6] MandlerR., KobayashiH., HinsonE.R., et al.. Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity. Cancer Res, 2004, 64(4): 1460-1467

[7] ChenH., GaoJ., LuY., et al.. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy. J Control Release, 2008, 28(3): 209-216

[8] MoliterniA., MenardS., ValagussaP., et al.. HER2 overexpression and doxorubicin in adjuvant chemotherapy for respectable breast cancer. J Clin Oncol, 2003, 21(3): 458-462

[9] JunttilaT.T., TannerM., IsolaJ.. Targeted cytotoxic drugs emerging for cancer therapy. Duodecim, 2011, 127(4): 343-349

[10] FuY., LiS., ZuY., et al.. Medicinal chemistry of paclitaxel and its analogues. Curr Med Chem, 2009, 16(30): 3966-3985

[11] SchraderC., KeussenC., BewigB., et al.. Symptoms and signs of an acute myocardial ischemia caused by chemotherapy with Paclitaxel (Taxol) in a patient with metastatic ovarian carcinoma. Eur J Med Res, 2005, 10(11): 498-501

[12] CruzA., TemuT., Hines-TelangG., et al.. Paclitaxel-induced neutrophilic adverse reaction and acral erythema. Acta Derm Venereol, 2011, 91(1): 86-87

[13] RaoS.C., ChuJ.J., LiuR.S., et al.. Synthesis and evaluation of [14C]-labelled and fluorescent-tagged paclitaxel derivatives as new biological probes. Bioorg Med Chem, 1998, 6(11): 2193-2204

[14] EricksonH.K., WiddisonW.C., MayoM.F., et al.. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem, 2010, 21(1): 84-92

[15] BurkeP.J., TokiB.E., MeyerD.W., et al.. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system. Bioorg Med Chem Lett, 2009, 19(1): 2650-2653

[16] SafavyA., BonnerJ.A., WaksalH.W., et al.. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery. Bioconjug Chem, 2003, 14(2): 302-310

[17] LiuD., RaoZ., ChenZ., et al.. Killing effect of anti-HER2 monoclonal antibody-TAX immunoconjugate on the tumor cells in vitro. Chin Hosp Pharm J (Chinese), 2007, 27(1): 10-13

[18] GaoY., WuQ., LiangX., et al.. Effect of anti-HER-2 engineered antibody chA21 on MMP-2 and TIMP-2 expression of human ovarian cancer SKOV3 cells. J Si’An Jiaotong Univ (Medical Sci), 2007, 28(4): 368-371

[19] HuangS.S., LiuR., QuY.X., et al.. Fluorescent biological label for recognizing human ovarian tumor cells based on fluorescent nanoparticles. J Fluoresc, 2009, 19(6): 1095-1101

[20] SunY., YuF., SunB.W., et al.. Antibody-drug conjugates as targeted cancer therapeutics. Yaoxue Xuebao (Chinese), 2009, 44(9): 943-952

[21] WeinerL.M.. An overview of monoclonal antibody therapy of cancer. Semin Oncol, 1999, 26(4Suppl12): 41-50

[22] MartinC.G.. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev, 2001, 53(2): 172-216